SurasakPhuphanichMDFAAN

Neurology • Los Angeles, CA

Neurooncology

Senior Neurologist/Neuro-Oncologist Consultant

Join to view full profile

Dr. Phuphanich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Phuphanich's full profile

Already have an account?

Office
11949 Jefferson Blvd. Ste 102
Los Angeles, CA 90230
Phone+1 424-257-8869

Fax+1 310-602-6446

Summary

My main clinical and research interests are drug delivery with nano-particle through blood brain barrier (BBB) and drug discovery with focus on promising new targeted therapeutic agents i.e. M-Tor inhibitor, EGFR-TKI, VEGFR, Monoclonal antibody, Gene therapy and Immunotherapy with Vaccine and Stem cell for different specific cancer cell targets including correlation with proteinomic, genomic profile in order to avoid major side effects and maintain high quality of life in this group of patients with the ultimate goal of offering personalized Neuro-Oncology medicine for every patient with brain cancer. I have more than 25 years of experience in this field for translational clinical research.

Education & Training

University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1978 - 1979
Ascension Illinois/Saint FrancisInternship, Internal Medicine, 1977 - 1978
Mahidol University Faculty of MedicineClass of 1975
Mahidol UniversityB.S., Faculty of Science, 1973

Certifications & Licensure

CA State Medical License 2006 - 2026
OR State Medical License 2022 - 2025
AZ State Medical License 2016 - 2021
FL State Medical License 1983 - 2009
GA State Medical License 2003 - 2009
IL State Medical License 1978 - 1984
American Board of Psychiatry and Neurology Neurology
United States Department of Justice Drug Enforcement Administration (DEA)

Awards, Honors, & Recognition

LA’s Top Doctors, Los Angeles Magazine Los Angeles Magazine, 2021
Top Doctors:LA Area Castle Connolly, 2013, 2016
Top's American Doctors for Cancer Castle Connelly Medical Ltd, 2006-2016
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Top Doctors for Southern California Castle Connelly Medical Ltd, 2012-2013
Best Doctors Best Doctors, Inc, 2011-2014
Tops American Oncologist Award Consumer Research Council, 2009-2012
Patients Choice Award MDs Medical Inc, 2008-2012
Top Doctor in July Issue Atlanta Magazine, 2007
Atlanta Magazine: Top Doctors Castle Connolly, 2007
Tops American Physicians Award Consumer Research Council, 2006
Americas Top Doctors for Cancer Castle Connelly Medical Ltd, 2006, 2009-2015
Recipient of NABTT Award for Best Quality of Data Management 2005
Georgia Cancer Coalition Distinguished Clinical Investigator Professorial Award 2004-2007
Twenty Years of Continuous Service Award University of South Florida, College of Medicine, 2003
Recipient of NABTT Award for Best Quality of Data 1998-1999
Recipient of NABTT Award for Best Accrual to Clinical Trial 1998-1999, 2001-2005
Scholar-Scientist Award University of South Florida, College of Medicine, Department of Neurology, 1997-1998, 2001-2002
Dedicated Service Award University of South Florida, College of Medicine, Department of Neurology and H. Lee Moffitt Cancer Center and Research Institute, 1996
Clinician, Scholar of the Year Award University of South Florida, College of Medicine, Department of Neurology, 1996
Marquis Who's Who in the World 1995
Marquis Who's Who in the South and Southwest 1994
Neuro-Oncology Award Department of Neurology, USF College of Medicine, 1993
Who's Who among Rising Young Americans 1992
Special Award, Founding Physician H. Lee Moffitt Cancer Center and Research Institute, 1986
Marquis Who's Who, Directory of Medical Specialists 1984
Research Fellowship Award Association of Brain Tumor Research, 1982, 1984
Fellowship Award American Cancer Society, 1982-1983
National Scholastic Achievement Award The King of Thailand, 1969
Top's American Physician Award Consumer Research Council
Join now to see all

Clinical Trials

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma Start of enrollment: 2002 Jun 01
Completed
Phase 1
Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas Start of enrollment: 2004 Mar 01
Completed
Phase 1
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma Start of enrollment: 2007 May 01
Completed
Phase 1
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2014 Jan 08
Completed
Phase 1
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

811 citations
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon, Alba A. Brandes, Antonio Omuro, Paul Mulholland, Michael Lim
JAMA Oncology. 2020-07-01
170 citations
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S. El-Deiry, Richard M. Goldberg, Heinz-Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney
CA. 2019-07-01
410 citations
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Gli...
Tracy T. Batchelor, Paul Mulholland, Bart Neyns, L. Burt Nabors, Mario Campone
Journal of Clinical Oncology. 2013-09-10

Journal Articles

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma
David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation ...
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli VK, LoghinM, Paleologos N, Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont I..., J Neurooncol, 1/1/2015
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ..., Neurology, 1/1/2015
Phase I, randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD, Neuro-Oncol, 1/1/2014
Phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
Chamberlain M, Grimm S, Recht L, Zhu J, Rosenfeld S, Fadul C, J Neurooncol, 1/1/2014
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent gli...
Batchelor T, Mulholland P, Neyns B, Nabors B, Campone M, Wick A, Mason W, Mikkelsen T, J. Clin Oncol, 1/1/2013
Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors
Saria MG, Corle C, Hu J, Rudnick JD, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Le..., J Neurosurg, 1/1/2013
New Approaches to Brain Tumor Therapy Consortium NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurre...
Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA, Neuro Oncol, 1/1/2013
New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma
Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA, Neuro Oncol, 1/1/2011
Phase I and pharmacokinetic study of COL 3 in patients with recurrent high grade gliomas
Rudek M New PZ, Mikkelsen T, Alavi J, Nabors L, Grossman SA, Piantadosi S, Fisher JD, J Neurooncol, 1/1/2011
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
Lai A, Tran A, Phioanh L, Nghiemphu, Pope WB, Soli OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Feh..., J. Clin Oncol, 1/1/2011
A phase I, II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high grade gliomas
Peereboom D, Carson KA, Supko J, Batchelor T, Lesser G, Mikkelson T, Grossman S, J. Neurooncol, 1/1/2010
A Phase I Evaluation of the Safety of Bortezomib with Biologic Proteosome 20S Activity Correlation and the Effects of Anticonvulsants in Adults with Recurrent Malignan...
Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson J,, J. Neurooncol, 1/1/2010
DR5 mediated controls caspase 8 cleavage and iniation of apoptosis in human glioblastomas
Bellail AC, Tse MC, Song, JH, Olsen JJ, Sun SY, Hao C, J. Cell. Mol Med, 1/1/2010
Phase I Analysis of BCNU Impregnated Biodegradable Polymer Wafers followed by Systemic Interferon alpha2b in Adult with recurrent Glioblastoma Multiforme
Olson JJ, McKenzie E, Megan SM, Zhang Z, Brat D, J. Neurooncol, 1/1/2008
A Phase I Evaluation of the Safety of Escalating Doses of Atrasentan in Adults with Recurrent Malignant Glioma
Carson K, Grossman SA, Lesser G, Olson J, Desideri S, Mikkelsen T, Fisher J, Neuro Oncol, 1/1/2008
Phase I Clinical Trial and Pharmacokinetic Study of Karenitecin in the treatment of Recurrent Malignant Gliomas
Grossman SA, Supko J, Carson K, Batchelor T, Peereboom D, Nabors G, Lesser G, Desideri S, Hausheer F, Neuro Oncol, 1/1/2008
Lipid rafts and nonrafts mediate TRAIL induced apoptic and non apoptic signals in non small cell lung carcinoma cells
Song JH, Tse MC, Bellail A, Khuri Fadlo, Kneteman NM, Hao C, Cancer Research, 1/1/2007
A Pharmacokinetic Study of intra CSF (Cerebrospinal fluid) Encapsulated Cytarabine (Depocyt) for the treatment of Neoplastic Meningitis in patients with Leukemia, Lymp...
Bernard M, Braeckman R, Chamberlain M, J. Neurooncol, 1/1/2007
Neurologic improvement after high dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell an...
Phuphanich S, Brock C, J. Neurooncol, 1/1/2007
The Effect of Enzyme Inducing Anti-Seizure Drugs on the Pharmacokinetics and Maximum Tolerated Dose of Procarbazine Hydrochloride
Grossman SA, Supko J, Batchelor T, Lesser G, Mikkelsen, Alivi J, Carson K, Fisher J., Clinical Cancer Research, 1/1/2006
Treatment related myelitis in hodgkin’s lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature
Gatcombe H, Lawson J, Crocker I, J. Neurooncol, 1/1/2006
A multicentre, randomized, double blind, placebo (PB) controlled trial of Marimastat (MT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) following ...
Levin VA, Yung WK, Forsyth P, Mastro R, Perry J, Elliott M, Baillet M, J. Neurooncol, 1/1/2006
Phase II trial of Copper Depletion as for the Angiosuppresive treatment of Newly Diagnosed Glioblastoma Multiforme
Brem S, Grossman S, Carson K, New P, Alavi J, Mikkelsen T, Priet R, Neuro Oncology, 1/1/2005
Phase I, Open Label, Dose Escalation, MultiInstitutional Trial of Intratumoral Injection with an EIB Attenuated Adenovirus, ONYX 015, into Recurrent Malignant Gliomas
Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg, FH, Barker F, Kracher J, Grossman SA, Fisher J, Priet R, Rosenblum M, Mikkelsen T, Olson J, Markert J, Freeman S, K..., Molecular Therapeutic, 1/1/2004
Join now to see all

Abstracts/Posters

Nanoconjugates for inhibition of laminin 411-integrin B1 Dll4 Notch1 pathway to treat glioblastoma multiforme
Gangalum PR, Ljubimov AV, Chesnokova A, Konda B, Ding H, Portilla-Arias J, Mamelak A, Bannykh S, Rudnick J, Hu J, Black KL, Ljubimova JY, Cancer Res, 1/1/2014
A randomized, double blind, controlled phase II trial of dendritic cell (DC) vaccination with ICT107 in newly diagnosed glioblastoma (GBM) patients
Wen P, Reardon D, Armstrong T, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peerboom D, Markert J, Grewal J, LaRocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G..., American Society of Clinical Oncology, Chicago, IL, 1/1/2014
BTTC08 01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT prom...
Raizer J, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli V, Loghin M, Paleologos N., Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-L..., American Society of Clinical Oncology, Chicago, IL, 1/3/2012
A randomized, double blind, controlled phase IIb study of the safety and efficacy of ICT 107 in newly diagnosed patients with glioblastoma multiforme following resecti...
Hawkins E, Aiken R, Chandler J, Fink K, Glantz M, Grewal J, Gruber M, Kesari S, Landolfi J, LaRocca R, Lesser G, Markert J, Mayer T, O'Rourke D, Peereboom, American Society of Clinical Oncology, Chicago, IL, 1/3/2012
The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with...
Rudnick, J, Hu J, Luptrawan A, Wheeler C, Mazer M, Nuno M, Chu R, Black K, Yu J, American Society of Clinical Oncology, Chicago, IL, 1/3/2012
Retrospective Analysis of Glioblastoma Patients Treated with Bevacizumab who Presented with Multifocal Disease at Diagnosis
Hu J, Nosova K, Nuno M, Yi A, Elramsisy A, Mukherjee D, Rudnick J, Bannykh S, Yu J, Black K, Patil C., American Society of Clinical Oncology, Chicago, IL, 1/3/2012
Correlation of Survival with Tumor Antigen Expression in Patients with Newly Diagnosed Glioblastoma Receiving a Multi Epitope Pulsed Dendritic Cell Vaccine
Wheeler C, Rudnick J, Mazer M, Nuno M, Fan X, Bender J, Hawkins E, Patil C, Black K, Yu J, American Society of Clinical Oncology, Chicago, IL, 1/3/2012
Phase II study of monthly Pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Norden D, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser GJ, Raizer J, Batchelor EC, Quant R, Beroukhim T, Kaylee A, Muzikansky A, Ciampa L..., American Society of Clinical Oncology, Chicago, IL, 1/4/2011
Phase 2 study of verubulin (MPC 6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab
Kim L, Chamberlain M, Zhu J, Raizer J, Grimm S, Fadul C, Rosenfeld S, Balch A, Pope C, Brulotte M, Beelen A, Recht L., American Society of Clinical Oncology; J Clin Oncol, Chicago, IL, 1/1/2011
Glioma associated antigens associated with prolonged survival in a phase I study of ICT 107 for patients with newly diagnosed glioblastoma
Wheeler C, Rudnick J, Mazer M, Nuno M, Fan X, Bender J, Hawkins E, Black K, Yu J, American Society of Clinical Oncology; J Clin Oncol, Chicago, IL, 1/1/2011
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21out of 28 days) in the treatment of patients with recurrent glioblastoma
Eisenstat D, Nabors L, Mason W, Perry J, Shapiro W, Kavan P, Fu Y, Cong X, Shahidi M, Reardon D., American Society of Clinical Oncology; J Clin Oncol, Chicago, IL, 1/1/2011
Phase I II Study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma
Reardon DA, Thurm H, Fink K, Giglio P, Shapiro W, LaRocca R, Mikkelsen T, Portnow J, Schiff D., American Society of Clinical Oncology; Proc Am Soc Clin Oncol, Chicago, IL, 1/1/2010
Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)
Rudnick J, Chu R, Mazer M, Wang H, Serrano N, Richardson J, Wheeler C, Black K, Singh M, Yu J, American Society of Clinical Oncology; Proc Am Soc Clin Oncol, Chicago, IL, 1/1/2010
A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral ...
Recht LD, Mechtler L, Hormigo A, Hines V, Milsted R, O'Connor PC, Ryan RP, Wong ET, ProcAm Soc Clin Oncol, 1/1/2009
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for pa...
Rudnick J, Chu R, Mazer M, Wang H, Serrano N, Francisco F, Black KL, Wheeler C, Yu, Proc Am Soc Clin Oncol, 1/1/2009
Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma mult...
Lai A, Nghiemphu P, Green R, Spier L, Peak S, Fehrenbacher L, Kolevska T,Polikoff J, Cloughesy T., Proc Am Soc Clin Oncol, 1/1/2009
Phase I Study of getifinib and rapamycin in adult patients with recurrent glioblastoma multiforme (GBM).
Chu R, Yu J, Black K., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Proc Am Soc Clin Oncol, San Francisco, CA, 2007, 1/1/2008
New Approaches to Brain Tumor Therapy (NABTT) CNSConsortium. A phase I study of SDX 102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas
Chamberlain M, Mikkelsen T, Ye X, Grossman SA, Batchelor T, Lesser G, Fisher J, Desideri S, Proc Am Soc Clin Oncol, 1/1/2007
A phase I trial of sorafenib (BAY 43 9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
Nabors L, Rosenfeld M, Chamberlain M, Batchelor, Supko J, Desideri S, Xiaobu Y, Wright J, Grossman S., Proc Am Soc Clin Oncol, 1/1/2007
Phase I trial of Bortezomib in adults with recurrent malignant glioma
Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J., Proc Am Soc Clin Oncol, 1/1/2006
Phase I Analysis of Systemic Interferon alpha Utilized with Gliadel in subjects with recurrent Glioblastoma Multiforme
McKenzie E, Greiner K, Shire K, Olson JJ, Neurology, 1/1/2006
Intratumoral pharmacokinectics dtermined with microdialysis in a patient with glioblastoma multiforme following systemic administration of high dose methotrexate
OlsonJJ, Supko J, McKenzie E, Grossman SA, Proc Am Soc Clin Oncol, 1/1/2005
NABTT 2111: A Phase I trial of BMS-247550 for patients with recurrent high-grade gliomas
Peereboom D,Batchelor T, Lesser G, Mikkelsen T,Carson K, Desideri S, Fisher J, Grossman SA, Proc Am Soc Clin Oncol, 1/1/2005
Phase I study of Karenitecin in the treatment of recurrent malignant gliomas (MG)
Lesser GJ, Grossman SA, Carson KA, Batchelor T, Peereboom D, Nabors LB, Supko J, Hausheer F, Proc Am Soc Clin Oncol, 1/1/2005
Evaluation of safety and tolerance of escalating doses of RSR-13 administered with dose of BCNU every six weeks in patients with recurrent malignant gliomas: Results o...
New PZ, Grossman S, Mikkelsen T, Batchelor T, Carson K, Fisher J, Craig M, Cagnoni P, Proc Am Soc Clin Oncol, 1/1/2004
Join now to see all

Lectures

Advances in Neuro-Oncology 2015: Biomarker, Liquid Biopsy Immuno-Oncology, NovoTTF
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand - 1/16/2015
Targeted Therapy for Brain Cancer: Early Detection and New Biomarker
Mahachai Hospital Group, Samutsakhon, Thailand - 1/15/2015
Immunotherapy for Brain cancer: Vaccine, ICT 107 Anti PD1 PD L1 Antibody
Houston Methodist Hospital, Houston, TX - 1/24/2014
Immunotherapy for Brain cancer: Vaccine, PD1 PD-L1 Antibody
Sydney, Australia - 1/17/2014
Breakthrough Brain Cancer Immunotherapy: Vaccine and Anti PD 1 PD L1
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand - 1/4/2014
Immunotherapy for Brain Cancer: Vaccine ICT 107 ANTI PD 1 PP L1 ANTIBODY
Siriraj Hospital, Bangkok, Thailand - 1/4/2014
Phase I trial of a multi-epitope pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Leuven, Belgium - 1/7/2012
Biomarker for Glioma: Prognostic or Predictive and ASCO NeuroOncology
Cedars Sinai Medical Center - 1/28/2011
Update Treatment in Gliomas
Dusit Thani, Mahidol University, Bangkok, Thailand - 1/20/2011
Vaccine Immunotherapy Targeting Stem Cell for Brain Cancer
Chaophya Hospital, Bangkok, Thailand - 1/19/2011
A Multi-epitope pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma demonstrates correlated survival and tumor antigen expression
Aspen, CO - 1/2/2011
Personalized Medicine for Brain Cancer: Vaccine Immunotherapy
University of California, Irvine, 2010; Dusit Thani, Mahidol University, Bangkok, Thailand - 1/1/2011
Future Directions in Nanomedicine, BBB Modification and Vaccine Immunotherapy for Brain Cance
University of California, San Diego - 1/14/2010
Personalized Medicine for Brain Cancer
Cedars Sinai Medical Center - 1/22/2009
Bio-Chemotherapy
Ritz Carlton, Marina Delray - 1/14/2009
Novel Bio-Chemotherapy for Brain Cancer
Gabon, Africa - 1/31/2008
Pitfall in Diagnosis of Brain tumor and Treatment of Low Grade Glioma
Cedars Sinai Medical Center - 1/26/2008
Emerging Molecular Targeted Therapy of Brain Cancer and Research at Cedars
Las Vegas - 1/11/2008
Future Direction of Molecular Targeted Therapy for Brain Cancer
Cedars Sinai Medical Center - 1/10/2008
Advances in Management of Metastatic Brain Cancer and Leptomeningeal Disease
Bangkok, Thailand - 1/1/2008
Emerging Molecular Targeted Therapy for Brain Cancer
Boca Raton Community Hospital, Boca Raton, FL, 2005; Cedars Sinai Medical Center - 1/1/2008
New Approaches to Low Grade and High Grade Glioma
Bangkok, Thailand - 1/1/2008
Molecular Targeted Therapy for Brain Cancer
Bangkok, Thailand - 1/1/2008
Emerging Molecular Targeted Therapy for Brain Cancer Research Seminar
San Diego; Cedars Sinai Medical Center - 1/1/2008
Molecular Targeted Therapy of Brain Tumor
Columbus, GA - 1/27/2007
Join now to see all

Authored Content

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020

Press Mentions

Update: 50 Percent of Patients in New Brain Cancer Study Alive After Five YearsNovember 24th, 2013
Vaccine Targets Malignant Brain Cancer Antigens, Significantly Lengthens SurvivalAugust 15th, 2012
Vaccine Study Supports Immune Targeting of Brain TumorsJune 17th, 2011